fda indications for tirzepatide is approved Semaglutide vs. Tirzepatide: Which Weight Loss Treatment Right You? Choosing between Back to routine postings! Here's

Similar content being viewed by others Subjects Main Glucagon-like peptide-1 (GLP-1) analogs and DPPIV inhibitors are increasingly used long term in patients with diabetes mellitus worldwide

GLP-1 medications slow gastric emptying, allowing intestinal bacteria more time to ferment food and produce gas Gas, bloating, and flatulence are classified as common side effects, though frequency varies between products and individuals Symptoms typically emerge during initial treatment or dose escalation and often improve as the body adapts Dietary modifications, smaller meals, and gradual fibre adjustment can help manage gastrointestinal symptoms Severe abdominal pain, persistent vomiting, or signs of pancreatitis or gallbladder disease require prompt medical attention Table of Contents What Are GLP-1 Medications and How Do They Work

More severe issues of GLP-1s can include: Pancreatitis, or severe abdominal pain radiating to the back, and vomiting Bowel obstruction, which consists of severe abdominal pain, vomiting, bloating, and constipation Severe gastroparesis, a chronic condition characterized by delayed stomach emptying without a physical blockage Identifying the Signs of Pancreatitis and Obstruction These can seem similar to many of the common side effects, so its important to know the difference

The post hoc analysis of the STEP programme reported depressive symptoms in 2.8% of semaglutide patients against 4.1% on placeboa figure that looks reassuring until you notice the population was mostly nondiabetic and on subcutaneous 2.4 mg, which tells us nothing about lower doses of the oral drug in people with T2DM ( The FAERS signal (a reporting odds ratio of 1.87 for depression) and the adjusted ratio of 1.70 for depressed mood disorders from VigiBase both fit a risk that shows up at the level of the individual patient, even when the randomised trials, looking at groups, do not see it ( A propensity-matched cohort study in 162,253 patients found a 195% higher risk of major depression with GLP-1 RA treatment compared with matched controls ( 5.5 Clinical implications A few practical lessons come out of this case